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Sensorineural hearing loss (SNHL) is a common clinical condition resulting fromdysfunction
in one or more parts in the auditory pathway between the inner ear and auditory cortex.
Despite the prevalence of SNHL, little is known about its etiopathology, although several
mechanisms have been postulated including ischemia, viral infection or reactivation, and
microtrauma. Immune-mediated inner ear disease has been introduced and accepted as
one SNHL pathophysiology; it responds to immunosuppressive therapy and is one of
the few reversible forms of bilateral SNHL. The concept of immune-mediated inner ear
disease is straightforward and comprehensible, but criteria for clinical diagnosis and the
precise mechanism of hearing loss have not been determined. Moreover, the therapeutic
mechanisms of corticosteroids are unclear, leading to several misconceptions by both
clinicians and investigators concerning corticosteroid therapy. This review addresses our
current understanding of the immune system in the inner ear and its involvement in
the pathophysiology in SNHL. Treatment of SNHL, including immune-mediated inner ear
disorder, will be discussedwith a focus on the immunemechanism and immunocompetent
cells as therapeutic targets. Finally, possible interventions modulating the immune system
in the inner ear to repair the tissue organization and improve hearing in patients with SNHL
will be discussed. Tissue macrophages in the inner ear appear to be a potential target for
modulating the immune response in the inner ear in the pathophysiology of SNHL.
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INTRODUCTION
Sensorineural hearing loss (SNHL) is a collection of common
auditory disorders resulting from dysfunction of the inner ear,
auditory nerve, or the auditory processing pathway in the cen-
tral nervous system. SNHL comprises a wide variety of auditory
disorders including sudden deafness, age-related hearing loss,
noise-induced hearing loss, and Meniere’s disease. To date, very
little of the SNHL pathophysiology is known because biopsy of the
human inner ear is not feasible. Among the purposedmechanisms,
immune-mediated SNHLhas been introduced and accepted in the
last three decades.
The inner ear has been thought of as an immune privileged
organ for a long time. The cochlea has no lymphatic drainage,
and the blood-labyrinth barrier is tightly controlled to separate
the cochlear microenvironment from the circulation. In addi-
tion, the concentration of immunoglobulin in the cochlear ﬂuid
is 1/1,000 of the concentration in the cerebrospinal ﬂuid (Harris
andRyan, 1984). McCabe (1979) introduced the clinical deﬁnition
of autoimmune inner ear disease as rapidly progressive bilateral
hearing loss that responds to corticosteroid and immunosuppres-
sive therapy. Corticosteroids have been widely used as the ﬁrst
and only regimen to treat virtually all types of SNHL with sud-
den onset or rapid progression even before McCabe’s report. The
anti-inﬂammatory and immune suppressive functions of corticos-
teroids led to their common use for hearing loss, especially when
inﬂammation or an immunological disorder is suspected. Despite
the common use of corticosteroids for inner ear disorders, our
understanding of their role in the pathogenesis of reversible hear-
ing loss remains limited. Steroid-responsive hearing loss does not
always indicate an underlying inﬂammation or immune disorder
in the inner ear (Trune and Canlon, 2012). Topical application
of corticosteroids in the tympanic cavity has also been reported in
patients unable to tolerate systemic treatment due to global adverse
effects (Kakehata et al., 2006; Han et al., 2009), and the functional
mechanisms of systemic and topical corticosteroid application
supposedly differ. Therefore, a better understanding of the inner
ear immunology and mechanisms of corticosteroids in the inner
ear would enable development of a more sophisticated therapy
for SNHL, including immune-mediated inner ear disease. In addi-
tion, alternative strategies of modulating immune activity without
corticosteroids are desirable for treating certain types of SNHL.
In this review, we will discuss the characteristics and suspected
pathophysiology of clinical hearing loss mediated by the immune
system. Second, we will describe the current understanding of
the inner ear immune system and will explore recent advances
in both basic and clinical research of the mechanism of corticos-
teroid therapy in the inner ear. Finally, we will discuss current
and potential SNHL therapies, including treatments targeting
immune-mediated inner ear disease.
PATHOPHYSIOLOGY OF SNHL FROM AN IMMUNOLOGICAL
VIEWPOINT
The pathophysiology of organ-speciﬁc autoimmune disease
is believed to be initiated by three primary mechanisms:
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(i) production of autoantibodies against tissue antigens,
(ii) deposition of antigen–antibody complexes in tissue, and
(iii) inﬁltration and destruction of tissue by speciﬁc cytotoxic T-
cells. Todate, themechanismsof hearing loss in immune-mediated
inner ear disease has yet to be determined, and none of the three
described pathophysiology mechanisms have been reported in the
human inner ear.
Immune-mediated inner ear disease was originally deﬁned by
McCabe (1979), who stated that idiopathic bilateral SNHL pro-
gresses to deafness over weeks or months, not hours, days, or
years, and responds to corticosteroid and immunosuppressive
therapy. The term of autoimmune inner ear disease refers to a
pathology restricted to the inner ear. The time course of hear-
ing loss distinguishes immune-mediated inner ear disease from
sudden deafness or age-related hearing loss. Although this clin-
ical entity is probably immune-mediated as immunosuppressive
agents are effective, there is no direct evidence that the condi-
tion is autoimmune in etiology because diagnostic biopsy of the
human inner ear is not feasible. Moreover, there are no uni-
formly accepted diagnostic criteria of immune-mediated inner
ear disease. The presence of bilateral SNHL of at least 30 dB with
evidence of progression in at least one ear on two serial audio-
grams performed less than 3 months apart is often used as case
criteria (Moscicki et al., 1994). Fluctuations in hearing may occur,
and immune-mediated disease is one of the few reversible causes
of SNHL. Further study is still required to determine the patho-
physiologic mechanisms underlying immune-mediated inner ear
disease.
The pathology of Meniere’s disease has historically been
deﬁned as an inner ear disorder presenting with endolym-
phatic hydrops. It is well known that some patients with
Meniere’s disease show remarkable recovery from ﬂuctuating
and refractory SNHL or vertigo following systemic corticos-
teroid treatment; therefore, an immune-mediated mechanism has
been implicated in the pathology of Meniere’s disease (Hughes
et al., 1983; Derebery et al., 1991). In a study of patients with
Meniere’s disease, immunohistochemistry showed IgG deposi-
tion in the endolymphatic sac obtained by surgical biopsy in
10 of 23 patients (Dornhoffer et al., 1993). Alleman reported
that 3 of 30 (10%) patients with Meniere’s disease showed
a positive serum reaction against proteins extracted from the
endolymphatic sac of autopsy samples, and clinical data have
shown an association between immunoreactivity and the dis-
ease severity (Alleman et al., 1997), suggesting an autoimmune
component in some cases of Meniere’s disease. In contrast,
other studies report a relationship between herpes simplex virus
and the pathology of Meniere’s disease (Bergstrom et al., 1992;
Kumagami, 1996). Although it appears likely that an immune
reaction is involved in the pathophysiology of Meniere’s disease,
the mechanism of endolymphatic hydrops, whether caused by
viral infection, autoimmune reaction, or both, remains to be
elucidated.
Multisystemic, organ-nonspeciﬁc autoimmune pathology may
involve the inner ear, leading to secondary SNHL. A limited num-
ber of studies have evaluated human temporal bones frompatients
with autoimmune disease, such as Wegener granulomatosis,
polyarteritis nodosa, Cogan syndrome, and lupus (McCabe, 1989;
Moscicki et al., 1994). Some specimens showed ﬁbrosis and osteo-
neogenesis, consistent with the end stage of inﬂammation. Other
bones demonstrated atrophy of the stria vascularis, the organ
of Corti, and the spiral ganglion without evidence of inﬂam-
mation, ﬁndings consistent with ischemia. Dettmer et al. (2011)
reported that the temporal bones of Crohn’s disease patients
with granulomatous inner ear disease demonstrated mild chronic
inﬂammation, poorly deﬁned granulomas, and inﬁltration of
CD68-positive macrophages.
Cytomegalovirus (CMV) is the leading cause of human non-
hereditary congenital hearing loss. Approximately 10–20% of
children with congenital CMV infection exhibit varying degrees
of hearing loss (Barbi et al., 2003; Numazaki and Fujikawa, 2004).
However, the pathology of congenital CMV infection within the
inner ear is poorly understood. Various animal models have been
employed to study the pathology of SNHL caused by intrauterine
CMV infection (Woolf et al., 1989; Juanjuan et al., 2011; Wang
et al., 2013). Two studies using mouse CMV infection mod-
els reported that CMV DNA was detected in spiral ganglion
neurons and the stria vascularis (Juanjuan et al., 2011; Wang
et al., 2013), suggesting a potential therapeutic target in CMV-
induced SNHL. Multiple studies have focused on developing
effective vaccines or antiviral therapy for congenital CMV infec-
tion. Unfortunately, there is no clinically effective vaccine for
congenital CMV infection or CMV-induced SNHL (Arvin et al.,
2004).
Several mechanisms have been postulated as the pathophysiol-
ogy of sudden deafness, including microcirculatory disturbances
caused by thrombosis, microtrauma or rupture of endolymph,
viral infection or reactivation, and immune-mediated reaction.
One of the main pathophysiology theories of idiopathic sud-
den deafness is that viral infection or reactivation in the inner
ear damages critical structures in the cochlea. Increased serum
concentrations of antibodies against CMV, herpes zoster, herpes
simplex type 1, inﬂuenza B, and mumps have been reported in
patients with idiopathic sudden deafness (Merchant et al., 2008;
Pyykko and Zou, 2008). Cochlear enhancement on magnetic res-
onance imaging (MRI) is a potential sign of inﬂammation in the
inner ear and has been observed in some patients suffering from
sudden deafness (Stokroos et al., 1998). The inner ear enhance-
ment on MRI disappeared following resolution of hearing loss
in 2 of 12 patients with sudden deafness (Mark et al., 1992).
Garcia-Berrocal et al. (1997) reported a decreased concentration
of both CD4+ and CD8+ cells in patients compared to healthy
control subjects, suggesting an abnormal autoimmune response
in lymphocyte subpopulations in patients with sudden deafness.
In addition, western blot assay showed a response to recombinant
human heat shock protein 70, a non-speciﬁc heat shock protein,
in 19 of 58 (33%) patients with idiopathic SNHL (Tebo et al.,
2006). An analysis of 11 human temporal bones from patients
with sudden SNHL showed that the morphology of the stria vas-
cularis and spiral ligament were relatively preserved, supporting
a viral etiology rather than a vascular insufﬁciency (Linthicum
et al., 2013). These ﬁndings suggest that immune mechanisms,
including T cell-mediated and antibody responses, are involved,
at least in part, in the onset or progression of idiopathic sudden
deafness.
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EVIDENCE OF THE IMMUNE SYSTEM IN THE INNER EAR
As previously mentioned, the inner ear was believed to be
“immune-privileged” and to exclude all immunocompetent cells,
except in the endolymphatic sac, for a long time because chronic
degeneration without neutrophilic inﬁltration in the organ of
Corti has been described in patients with presbycusis or hear-
ing loss due to chronic noise exposure. However, Rask-Andersen
and Stahle (1979) initiated a new era of inner ear immunol-
ogy by describing intimate contact between the lymphocytes
and macrophages in the endolymphatic sac of guinea pigs.
This association suggested that two cell types mediated the
antigen-presenting process in the endolymphatic sac. The pres-
ence of immunocompetent cells and phagocytized antigen within
macrophages was also reported in the endolymphatic sac (Har-
ris et al., 1997). These ﬁndings revealed the speciﬁc role of the
endolymphatic sac in antigen processing and immune activity in
the inner ear. However, recent studies have demonstrated the pres-
ence of immunoreactive cells in other areas of the inner ear even
under normal conditions (Lang et al., 2006; Okano et al., 2008;
Sato et al., 2008). Lang et al. (2006) reported that bone marrow-
derived cells of hematopoietic origin migrate into the cochlea
and reside in the cochlear modiolus and the cochlear lateral wall.
They also showed that bone marrow-derived cells in the cochlea
express ion transporters such as the sodium/potassium/chloride
co-transporter or sodium/potassium-ATPase in the cochlear lat-
eral wall, which contains several types of ﬁbrocytes. In a study
using bone marrow-chimeric mice that were transplanted with
hematopoietic stem cells after receiving lethal systemic irradiation,
Okano et al. (2008) demonstrated that bone marrow-derived cells
reside as macrophages in the cochlea. They also reported that Iba-
1-positive macrophages were continuously and slowly replaced
by bone marrow-derived cells from the systemic circulation over
several months. Finally, Sato et al. (2008) reported that bone
marrow-derived cells expressing CX3CR1, a fractalkine recep-
tor speciﬁc to monocytes, natural killer cells, activated T-cells,
and tissue macrophages, reside in the spiral ganglion and spiral
ligament. In addition, they showed that CX3CR1-positive cells
were repopulated in the cochlea over several months. Collectively,
these ﬁndings indicate that the inner ear harbors immunocompe-
tent cells of hematopoietic origin normally, with most cells likely
to be tissue macrophages phenotypically. Although these tissue
macrophages are distributedprimarily in the spiral ganglion, spiral
limbus, and spiral ligament,macrophage-likemelanocytes are also
observed in the intermediate layer of the stria vascularis (Zhang
et al., 2012). These melanocytes reside adjacent to blood vessels
and are believed to be perivascular-resident macrophages that
contribute to the formation of the blood-intrastrial ﬂuid barrier
(Figure 1).
The role of cochlear macrophages and mechanisms of
macrophage migration into the cochlea remain largely unknown.
Previous studies demonstrated that injury of the auditory sensory
epithelium induces inﬂammation characterized by macrophage
inﬁltration into the chick basilar papilla (Warchol, 1997; Bhave
et al., 1998). A large increase in the number of CD45-positive
cells has been observed after noise exposure in the mouse
cochlea, suggesting inﬂammation caused by bone marrow-
derived cells (Hirose et al., 2005; Tornabene et al., 2006). The
FIGURE 1 | Distribution of cochlear macrophages. Schematic drawing
shows the cross section of the cochlear duct. Cochlear macrophages
reside in the spiral ligament and spiral limbus where ﬁbrocytes are located
to keep ion exchanges. In addition, macrophages are distributed in the
spiral ganglion. Finally, macrophage-like melanocytes are observed in the
intermediate layer of the stria vascularis.
number of cochlear macrophages is also increased after amino-
glycoside insult in both the spiral ganglion and spiral liga-
ment (Sato et al., 2010). These ﬁndings indicate that cochlear
macrophages play important roles in the onset and progression
of inﬂammation after damage to the cochlear sensory epithe-
lium. Macrophages in the cochlea are likely involved not only
in the degeneration of the organ of Corti, but also the stria vas-
cularis. Jabba et al. (2006) reported that hyperpigmentation of
the stria vascularis and reorganization of marginal cells occurs
in Slc26a4-null mice, a mouse model of Pendred syndrome, and
is associated with the invasion of CD68-positive macrophages.
Similar ﬁndings regarding hyperpigmentation of the stria vas-
cularis have also been reported in genetically modiﬁed mice
(Singh and Wangemann, 2008; Lu et al., 2012). The invasion
of macrophages is restricted to the degenerated stria vascularis,
suggesting contribution from the cochlear macrophages to degen-
eration or regeneration of the stria vascularis and the cochlear
lateral wall.
The number of cochlear macrophages is also increased by sys-
temic administration of macrophage colony stimulating factor
(Csf1), which is one of the primary regulators of mononuclear
phagocyte activation. The density of Iba1-positive macrophages
is increased in both the spiral ligament and spiral ganglion
1 day after administering Csf1 (Okano et al., 2008), but it
is unclear whether the increased macrophage population is
due to migration from the circulation or in situ prolifera-
tion in the cochlea. Yagihashi et al. (2005) also demonstrated
that topical administration of Csf1 ameliorates the degrada-
tion of auditory neurons following surgical injury in a rat
model. In addition, Csf1 was demonstrated to have neuro-
protective properties in an in vitro model of excitotoxicity
in hippocampal neurons, suggesting both direct and indi-
rect effects of Csf1 on survival of targeted cells (Vincent
et al., 2002). It is unknown whether the activation of tissue
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macrophages has protective or degenerative effects in the tar-
get organ, but control of macrophage activity through Csf1
administration is a potential approach for several inner ear
disorders.
Previous reports investigating in situ proliferation of cochlear
macrophages are controversial. Using Bromodeoxyuridine label-
ing, Hirose et al. (2005) reported that cochlear macrophages
do not proliferate after acoustic trauma. However, accord-
ing to the study done by Okano et al. (2008) a sub-
set of macrophages expressed Ki67, suggesting that resident
macrophages enter the cell cycle after migration following sur-
gical invasion of the cochlea. Although the precise nature of
migratingmacrophages is to bedetermined, cochlearmacrophages
are most likely responsible for several different inner ear
pathologies.
TISSUE MACROPHAGES IN THE INNER EAR
In general, adaptive immune cells play a major role in disease pro-
gression, and the innate immune system, primarilymonocytes and
macrophages, plays a central role in the onset of immune activity.
The concept of multiple macrophage activation states is not new,
but extending this idea to resident tissue macrophages has gar-
nered increased interest in recent years. Unfortunately, research of
peripheral macrophage polarizationmight not accurately describe
their central nervous system counterparts.
Macrophages are derived from monocyte precursors that
undergo tissue-speciﬁc differentiation and inﬁltrate the site of
infection or injury to produce inﬂammatory mediators. The cells
typically polarize into the pro-inﬂammatory M1 phenotype and
function as an effector of the Th1-mediated immune response.
TheM1polarization of macrophages is regulated by several factors
including the mineralocorticoid receptor (Lawrence and Natoli,
2011). In the normal course of inﬂammation, the immune process
is controlled, and M1-macrophages undergo apoptosis or switch
to the anti-inﬂammatory M2 phenotype, thereby halting inﬂam-
mation. However, if the inﬂammatory response of macrophages
is not controlled, it becomes pathogenic, resulting in signiﬁcant
levels of non-speciﬁc tissue damage and leading to inﬂamma-
tory and autoimmune diseases (Wynn et al., 2013). Therefore,
macrophage-targeted therapy is extremely relevant in improving
the prognosis of inﬂammatory diseases, particularly inﬂammation
in the inner ear.
Thought provoking observations have been obtained in stud-
ies of patients with human immunodeﬁciency virus (HIV),
speciﬁcally concerning macrophage function in the inner ear.
Monocytes and macrophages are susceptible to HIV infection and
are considered a main mechanism responsible for central nervous
system infection in areas containing perivascular macrophages
and parenchymal microglia (Burdo et al., 2013). Lin et al. (2013)
demonstrated that HIV infection is signiﬁcantly associated with
an increased risk of developing sudden deafness in patients aged
between 18 and 35 years. In addition, Assuiti et al. (2013) found
no direct association between anti-retroviral therapy and hearing
loss but stressed the need for future investigation of the causes and
associationbetween anti-retroviral therapy andhearing loss. These
data suggest that deﬁciencies in the macrophage and monocyte
lineage may lead to dysfunction in the inner ear and highlight the
important roles of macrophages in the maintenance of auditory
function.
Several surface markers have been used in the animal studies
of macrophages to immunohistochemically test their phenotypes
and distribution in the tissues. CD68 is a heavily glycosy-
lated transmembrane protein and is a common surface marker
expressed in all macrophages (Smith and Koch, 1987; Ramprasad
et al., 1996). F4/80 is a member of a gene family that includes
the human epidermal growth factor module-containing mucin-
like hormone receptor 1 and human CD97, and resides on the
surface of a family of cells that includes all well differentiated
members of the mononuclear phagocyte system. Although the
precise function of F4/80 is not completely understood as F4/80-
null mice have no remarkable phenotype, F4/80-positive cells
have many common features regardless of their tissue location
and are characterized by highly ramiﬁed cell shape (Hume et al.,
2002). Iba1 is a calcium binding protein speciﬁc to macrophages
that mediates calcium signals that may control migration and
phagocytosis in tissue macrophages (Imai et al., 1996). Report-
edly, tissue macrophages in the inner ear express Iba1 in addition
to F4/80 (Okano et al., 2008). Csf1r is an alternative surface
marker on macrophages and is thought to play key roles in
the proliferation, differentiation, and survival of macrophages
(Hume et al., 2002). In other categorical systems, the differenti-
ation of monocytes and macrophages is described based on the
expression of speciﬁc cell markers. If similar markers could be
identiﬁed in tissue macrophages or cells of monocyte lineage,
it may be possible to trace these cells along several different
points of the inner ear pathophysiology, including systemically
circulating monocytes, migrating monocytes, and resident tissue
macrophages.
CORTICOSTEROID THERAPY
Systemic or possibly local administration of corticosteroids is the
mainstay of treatment for SNHL, including immune-mediated
inner ear disease. However, there are limited prospective data
evaluating the appropriate dose, route, and length of corticos-
teroid treatment. In addition, although many patients experience
a short-term response to steroids, the response is generally
not sustained (Zeitoun et al., 2005). A prospective, random-
ized, controlled study in 116 patients with rapidly progressive,
bilateral SNHL reported that 57% of patients in the 1 month
prednisone challenge showed improved hearing, but adverse
effects such as hyperglycemia were observed in 14% of patients
(Alexander et al., 2009). A meta-analysis of the management
of idiopathic sudden SNHL performed by Spear and Schwartz
(2011) reported that intratympanic corticosteroids administered
as the primary treatment appeared equivalent to treatment with
high-dose oral prednisone. Furthermore, intratympanic admin-
istration of corticosteroids potentially recovered some degree
of hearing as a salvage therapy. These observations suggest
that the local administration of corticosteroids is beneﬁcial
through mechanisms distinct from those of systemic corticos-
teroid therapy.
Despite numerous clinical reports of corticosteroid treatment
for SNHL, the spontaneous rate of recovery in acute SNHL
complicates conclusions about corticosteroid efﬁcacy. To date,
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the mechanisms underlying ﬂuctuating SNHL in an immune-
mediated inner ear disease are unclear. We know little on how
corticosteroids work in the inner ear and which parts of the
inner ear are affected during reversible hearing loss. The expres-
sion of glucocorticoid receptors in the inner ear is limited to
the inner and outer hair cells, the spiral ganglion, and the
spiral ligament (Tahera et al., 2006; Meltser et al., 2009). In addi-
tion to glucocorticoid receptors, corticosteroids have a strong
afﬁnity for mineralocorticoid receptors. The use of systemic
mineralocorticoids alone or in combination with glucocorticoids
has not been evaluated in humans, but is apparently efﬁca-
cious in animal models (MacArthur et al., 2008). Because the
inner ear requires tight regulation of ion homeostasis in both
the perilymph and endolymph, the effect of corticosteroid ther-
apy through mineralocorticoid receptors should be considered
in the mechanism of action when treating SNHL. Moreover,
there are several questions on the assumptions which clinicians
and researchers take for granted. Do corticosteroids only sup-
press inﬂammation and immune response in the inner ear? Do
corticosteroids affect the inner ear speciﬁcally or do the sys-
temic effects of corticosteroids beneﬁt the inner ear disorder?
Does immune-mediated hearing loss always respond to corti-
costeroids? A better understanding of the immune-mediated
aspects of hearing loss and speciﬁc diagnostic assays would lead
to the development of immune-modulating therapy for sudden or
progressive SNHL.
McCabe recommended high-dose corticosteroids along with
cyclophosphamide therapy for prolonged treatment of immune-
mediated inner ear disease (McCabe, 1979). However, the
extended follow-up of patients treated with cyclophosphamide
revealed potential adverse effects and long-term morbidity and
mortality risks of the agent, particularly neoplasm development
in younger patients, which limited its use and prompted the
search for other immunosuppressive options (Harris et al., 2003;
Garcia-Berrocal et al., 2006).
Methotrexate has been used as a sparing treatment to con-
trol refractory immune-mediated SNHL. Salley et al. (2001)
reported improvement in the majority of 53 patients with
immune-mediated inner ear diseases who were treated with
low-dose methotrexate. Long-term, low-dose methotrexate ther-
apy appeared to be effective in at least some patients with
immune-mediated hearing loss that is refractory to tradi-
tional corticosteroid therapy (Matteson et al., 2001). By con-
trast, a randomized, double-blind, placebo-controlled trial in
2003 of immune-mediated inner ear disease suggested that
methotrexate does not appear to be effective in maintaining
the hearing improvement achieved with prednisone therapy
(Harris et al., 2003).
Azathioprine was also reported as an alternative option
in treating immune-mediated inner ear disease, although
reports were based on small case series and were inconclusive
(Lasak et al., 2001).
According to these ﬁndings, systemic immunosuppressives
such as methotrexate are effective in some patients with bilat-
eral, progressive, or ﬂuctuating SNHL, which indicates an
immune component in the pathophysiology of hearing loss.
However, the diagnostic criteria of immune-mediated inner
ear disease vary among previous reports. Clinicians and inves-
tigators should consider that patients with bilateral ﬂuctuat-
ing SNHL do not always have an immune disorder in the
inner ear.
RECENT ADVANCES AND FUTURE DIRECTIONS OF SNHL
TREATMENT
MOLECULAR-TARGETED DRUGS AND BIOLOGICAL AGENTS
Despite initial optimistic reports suggesting a therapeutic
effect of methotrexate, a recent study by Harris et al. (2003)
failed to demonstrate its efﬁcacy for long-term manage-
ment of immune-mediated inner ear diseases as mentioned
above. Instead, molecular-targeted drugs have garnered atten-
tion of investigators and clinicians in the ﬁelds of immunol-
ogy and audiology due to their speciﬁcity against thera-
peutic targets, resulting in less toxicity and fewer adverse
effects.
Etanercept is a fusion protein comprising two recombinant
tumor necrosis factor (TNF) receptors linked to the C por-
tion of human IgG1 (Mohler et al., 1993). A retrospective
case series by Rahman et al. (2001) examined the response to
etanercept in 12 patients with immune-mediated haring loss
responsive to high-doses of corticosteroids. Improvement or
stabilization of hearing and tinnitus was observed in 91% of
patients, suggesting that etanercept therapy is safe and may be
efﬁcacious in some patients with immune-mediated hearing loss.
By contrast, two studies reported that etanercept has no sub-
stantial efﬁcacy in improving hearing loss (Cohen et al., 2005;
Matteson et al., 2005). Further studies are needed evaluating alter-
native regimens that use etanercept or other anti-TNF-alpha
agents.
Inﬂiximab is another monoclonal antibody against TNF-
alpha that binds TNF-alpha and reduces its activity (Siddiqui
and Scott, 2005). A retrospective review of eight patients with
suspected immune-mediated hearing loss refractory to con-
ventional treatment examined the efﬁcacy of inﬂiximab on
hearing improvement; however, none of the patients exhibited
a positive response to inﬂiximab therapy based on objective
measurements (Liu et al., 2011). Monoclonal antibody ther-
apy directly targeting cells in the inner ear is unlikely to
be effective because the concentration of immunoglobulin is
much lower in this region than that in cerebrospinal ﬂuid
or blood due to tight regulation by the blood-labyrinthine
barrier. Accordingly, transtympanic administration of inﬂix-
imab was evaluated by Van Wijk et al. (2006) in nine patients
with immune-mediated hearing loss. Transtympanic admin-
istration of inﬂiximab resulted in hearing improvement and
reduced disease relapses, indicating the potential utility of local
administration of monoclonal antibody in treating inner ear
disease.
Adalimumab was also used to block TNF signaling in patients
with immune-mediated hearing loss, but reports were based on a
small number of cases (Morovic Vergles et al., 2010).
Rituximab is a genetically engineered chimeric monoclonal
antibody against CD20, which resides the surface of B cells.
The agent reduces autoantibody production both in circulat-
ing and tissue B cells, but does not affect plasma cells. A small
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pilot study in patients with immune-mediated inner ear dis-
eases was performed evaluating the efﬁcacy of rituximab in
treating hearing loss (Cohen et al., 2011). Further evaluation of
rituximab is encouraged using a properly designed randomized
study.
NUCLEIC ACID THERAPY
Nucleic acid therapy, including delivery of gene constructs to
increase or force expression in the targeted tissue, and small
interfering RNA to block expression of a speciﬁc gene, is a promis-
ing approach for treating inner ear disease. However, limited
access to the lesion site creates challenges in nucleic acid ther-
apy of the inner ear. Various studies employing animal models
utilize viral vectors to introduce the nucleic acid into the inner
ear, but there are toxicity and safety concerns associated with this
method, including immunogenicity and mutagenesis. Non-viral
vectors are advantaged by overcoming these limitations plagu-
ing viral vectors. Although nucleic acid therapy is challenging
in the in vivo setting, the development of novel delivery sys-
tems could lead to drastic advances in improving the prognosis
of patients with SNHL. Obviously, macrophages are a potential
target for nucleic acid therapy using novel delivery systems in the
inner ear, controlling not only inﬂammation and degeneration
of sensory organs, but also regeneration of the cochlear lateral
wall and innervation from the spiral ganglion neurons to hair
cells.
DELIVERY OF GENE MODIFIED MACROPHAGES
The last, but not least, the use of genetically modiﬁed monocytes
or macrophages as vectors should be considered for production
of therapeutic molecules or factors that promote regeneration
or regrowth of speciﬁc structures in the inner ear. This con-
cept is especially well suited for a secreted paracrine or endocrine
factor such as a hormone or growth factor. Because the inner
ear contains three ﬂuid-ﬁlled compartments, secreted factors
from genetically modiﬁed macrophages could potentially dif-
fuse throughout the inner ear without help from the blood or
lymphatic circulation. Although the use of genetically modi-
ﬁed cells as vectors of genes or pharmacotherapeutic reagents
is in the early stage (Hakuba et al., 2005; Okano et al., 2006;
Kesser and Lalwani, 2009), transplantation of genetically engi-
neered cells able to secrete speciﬁc metabolic or humoral cues
could augment pharmacologic immune modulation in the inner
ear. Delivery of genetically modiﬁed cells into the inner ear
could pose a major challenge because of the anatomical char-
acteristics of the inner ear. Monocytes and macrophages are
able to migrate into the inner ear in both pathologic and nor-
mal conditions (Hirose et al., 2005; Okano et al., 2008). Thus,
the human monocyte lineage could be isolated and cultured ex
vivo and genetically manipulated. Intravenous administration of
genetically modiﬁed monocytes could enable them to reach and
migrate into the inner ear, although tissue- or organ speciﬁcity
could be a potential problem to overcome in clinical applications
(Figure 2).
Apart from resident macrophages at the disease site, circulat-
ing monocytes are continuously recruited to meet the demands
of the inﬂammatory response and the expression of chemokines,
FIGURE 2 | Schematic depictions of a concept to utilize genetically
modified macrophages for the treatment of inner ear diseases.
Autologous monocyte lineage is taken from patient’s peripheral blood, and
transfected plasmids of targeted gene. After ex vivo culturing, genetically
modiﬁed monocytes are injected intravenously. Injected monocytes are
migrating into the inner ear to differentiate to tissue macrophages.
Genetically modiﬁed macrophages produce and secrete therapeutic
molecules which diffuse throughout the ﬂuid of the inner ear.
cytokines, and cell adhesion molecules. An alternative approach is
to facilitate phagocytosis of loaded delivery vehicles bymonocytes,
which then passively targets the site of disease due to themounting
immune response. The active targeting approach is most attrac-
tive and promising if the surface of the delivery vehicle can be
decorated with a ligand that selectively interacts with their tar-
get receptors. Further research evaluating the use of monocytes as
vehicles is desired.
CONCLUSION
In this review, we discussed the involvement of the immune sys-
tem in the pathology of SNHL, particularly the innate immune
system in the inner ear and the pathology of immune-mediated
inner ear disease. Recent advances in basic and clinical audiology
and immunology research has been rapid. Although there is still
much work to be done, we believe that the future of inner ear
immunology and SNHL treatment are bright and promising.
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